These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980 [TBL] [Abstract][Full Text] [Related]
8. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies. Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584 [TBL] [Abstract][Full Text] [Related]
9. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells. Zhuang X; Long EO Front Immunol; 2022; 13():840844. PubMed ID: 35585985 [TBL] [Abstract][Full Text] [Related]
10. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477 [TBL] [Abstract][Full Text] [Related]
12. CAR-NK Cells: From Natural Basis to Design for Kill. Khawar MB; Sun H Front Immunol; 2021; 12():707542. PubMed ID: 34970253 [TBL] [Abstract][Full Text] [Related]
13. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth. Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598 [TBL] [Abstract][Full Text] [Related]
14. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942 [TBL] [Abstract][Full Text] [Related]
15. Clinical development of natural killer cells expressing chimeric antigen receptors. Golden RJ; Fesnak AD Transfus Apher Sci; 2021 Feb; 60(1):103065. PubMed ID: 33468407 [TBL] [Abstract][Full Text] [Related]
16. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641 [TBL] [Abstract][Full Text] [Related]
17. CAR-NK cell in cancer immunotherapy; A promising frontier. Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690 [TBL] [Abstract][Full Text] [Related]
18. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting. Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562 [TBL] [Abstract][Full Text] [Related]
19. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape. Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337 [TBL] [Abstract][Full Text] [Related]
20. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. Roex G; Campillo-Davo D; Flumens D; Shaw PAG; Krekelbergh L; De Reu H; Berneman ZN; Lion E; Anguille S J Transl Med; 2022 Mar; 20(1):124. PubMed ID: 35287669 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]